The genomic landscape of circulating tumor DNA (ctDNA) was comparable to the landscape of tissue biopsies in a large study of patients with metastatic castration-resistant prostate cancer (mCRPC), according to researchers. The type and frequency of genomic alterations observed were largely similar in ctDNA and tissue, and there was high concordance for BRCA1/2 alterations. Comprehensive […]
Endocrine therapy is standard of care for estrogen-receptor positive (ER+) breast cancer, but only about half of women respond. At present, there is no method for identifying the women who are likely — and also unlikely — to respond. But a new approach looks to be useful: it involves a trial of estrogen and then […]
A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers. Researchers studied prostate cancer samples from 352 participants in the NRG/RTOG 9601 clinical trial, which compared radiation therapy […]
SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska's research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. Removing […]
A team of researchers from Stanford University in the U.S. and Southern University of Science and Technology in China has found evidence that suggests metastasis of cancerous tumors may get its start much earlier than previously thought. In their paper published in the journal Nature Genetics, the group describes their whole-exome sequencing analysis of multiple […]
